| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9283213 | Microbes and Infection | 2005 | 10 Pages |
Abstract
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
E. Rollman, A. BrÃ¥ve, A. Boberg, L. Gudmundsdotter, G. Engström, M. Isaguliants, K. Ljungberg, B. Lundgren, P. Blomberg, J. Hinkula, B. Hejdeman, E. Sandström, M. Liu, B. Wahren,